跳转至内容
Merck
CN

EHU140941

MISSION® esiRNA

targeting human BMF

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GAGGTACAGATTGCCCGAAAGCTTCAGTGCATTGCAGACCAGTTCCACCGGCTTCATGTGCAGCAACACCAGCAGAACCAAAATCGTGTGTGGTGGCAGATCCTCCTCTTCCTGCACAACCTTGCTTTGAATGGAGAAGAGAACAGGAACGGGGCAGGCCCTAGGTGAGGGTGGGCTGCCCTCTTCACATGGGGCACCAGGAACACCGTCTGGAACAGGAAGGACATCGGGCAGGACTGACACTGTGTCTTGTGAAATTGTTTTTTTGTTGTTATTTTGTGTTTTAATTTTTTTTAATTTCTCTCTGAGTGTACATACAACATACTCAAGCGGGACCTTCTTTCTCTGTCAGGCCCTTGACCTGGAATGGGGGCCTTTGTCAAACACTGTTGAAGGAGAGGCTGATGTGTCTGTGATGGTGAGAATTCCCA

Ensembl | human accession no.

ENSG00000104081

NCBI accession no.

NM_001003940

shipped in

ambient

storage temp.

−20°C

Quality Level

100

相关类别

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
QCS
KUT
KIT

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Y Kang et al.
Cell death & disease, 5, e1476-e1476 (2014-10-17)
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family members might offer an improved therapeutic approach. We
Kari J Kurppa et al.
Cancer cell, 37(1), 104-122 (2020-01-15)
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持